Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACCLAIM-CTA
2025-524858-34-00Phase 3Authorised
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2026
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial in atherosclerotic disease, coronary arteriosclerosis and hyperlipoproteinemia comparing Lepodisiran with Placebo to match LY (2 arms). Primary endpoint: Percent change from baseline in noncalcified plaque volume. Planned start Aug 2026; status: authorised.
02
Drugs
lepodisiran
03
Conditions
atherosclerotic diseasecoronary arteriosclerosishyperlipoproteinemia
Beyond the preview
Go deeper on 2025-524858-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524858-34-00.